A retrospective, cohort, multicenter study assessing the real-world use and effectiveness of dolutegravir-based regimens (DBRs) in patients with HIV-1 infection conducted using data from four National Health Service trusts using Climate-HIV
Latest Information Update: 14 Dec 2021
At a glance
- Drugs Abacavir/dolutegravir/lamivudine (Primary) ; Dolutegravir (Primary)
- Indications HIV-1 infections
- Focus Therapeutic Use
- 14 Dec 2021 New trial record